TABLE OF CONTENTS
1 INTRODUCTION 32
1.1 OBJECTIVES OF THE STUDY 32
1.2 MARKET DEFINITION 32
1.3 OVERVIEW OF ASIA PACIFIC FOOT AND ANKLE ALLOGRAFTS MARKET 32
1.4 LIMITATIONS 34
1.5 MARKETS COVERED 34
2 MARKET SEGMENTATION 37
2.1 MARKETS COVERED 37
2.2 GEOGRAPHICAL SCOPE 38
2.3 YEARS CONSIDERED FOR THE STUDY 39
2.4 CURRENCY AND PRICING 39
2.5 DBMR TRIPOD DATA VALIDATION MODEL 40
2.6 MULTIVARIATE MODELLING 43
2.7 END USER LIFELINE CURVE 43
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 44
2.9 DBMR MARKET POSITION GRID 45
2.10 MARKET APPLICATION COVERAGE GRID 46
2.11 VENDOR SHARE ANALYSIS 47
2.12 SECONDARY SOURCES 48
2.13 ASSUMPTIONS 48
3 EXECUTIVE SUMMARY 49
4 PREMIUM INSIGHTS 51
4.1 PORTERS FIVE FORCES 52
5 INDUSTRIAL INSIGHTS: 53
5.1 CONCLUSION: 53
6 ASIA PACIFIC FOOT AND ANKLE ALLOGRAFTS MARKET: REGULATIONS 54
6.1 U.S. 55
6.2 CANADA 56
6.3 EUROPE 56

7 MARKET OVERVIEW 58
7.1 DRIVERS 60
7.1.1 GROWING GERIATRIC POPULATION 60
7.1.2 INCREASE IN PREVALENCE OF MUSCULOSKELETAL DISORDER 60
7.1.3 INCREASE IN HEALTHCARE EXPENDITURE 61
7.1.4 INCREASE IN STRATEGIC INITIATIVES BY MAJOR MARKET PLAYERS 62
7.2 RESTRAINTS 63
7.2.1 STRINGENT REGULATORY 63
7.2.2 COMPLICATION AND RISK OF ALLOGRAFTS 63
7.3 OPPORTUNITIES 64
7.3.1 INCREASE IN NUMBER OF SPORTS INJURIES 64
7.3.2 RISE IN AWARENESS INITIATIVES ABOUT THE ALLOGRAFT PROCEDURE: 65
7.3.3 INCREASING RISK OF OSTEOPOROSIS AND OSTEOARTHRITIS: 66
7.4 CHALLENGES 67
7.4.1 COVID-19 IMPACT ON ASIA PACIFIC FOOT AND ANKLE ALLOGRAFTS MARKET 67
7.4.2 ALLOGRAFT IS OFTEN CONSIDERED TOO EXPENSIVE IN LOW-INCOME TO MIDDLE-INCOME COUNTRIES: 68
7.4.3 HIGHER ADOPTION OF ALTERNATIVE THERAPIES FOR THE TREATMENT OF FOOT AND ANKLE DISORDERS: 69
8 ASIA PACIFIC FOOT AND ANKLE ALLOGRAFTS MARKET, BY PRODUCT TYPE 70
8.1 OVERVIEW 71
8.2 ALLOGRAFT WEDGES 74
8.3 ALLOGRAFT TENDONS 74
8.4 ALLOGRAFT ACELLULAR DERMAL MATRIX 75
8.5 CARTILAGE ALLOGRAFT MATRIX 76
8.6 SKIN ALLOGRAFTS 77
8.7 AMNIOTIC MEMBRANES 78
9 ASIA PACIFIC FOOT AND ANKLE ALLOGRAFTS MARKET, BY SURGERY TYPE 79
9.1 OVERVIEW 80
9.2 ORTHOPEDIC RECONSTRUCTION 83
9.2.1 NON-UNIONS FRACTURES 84
9.2.2 ARTHRODESIS PROCEDURES 84
9.2.3 OSTEOTOMY PROCEDURES 84
9.3 CARTILAGE RESTORATION 84
9.3.1 TALAR DOME REPAIR 85
9.3.2 TIBIAL PLAFOND REPAIR 85
9.3.3 METATARSAL REPAIR 85
9.3.4 TALONAVICULAR JOINT REPAIR 85
9.3.5 SUBTALAR JOINT REPAIR 85
9.4 SOFT TISSUE TENDON & LIGAMENT REPAIR 85
9.4.1 TENDON AUGMENTATION 86
9.4.2 LIGAMENT REPAIR 86
9.4.3 FAT PAD REPLACEMENT 86
9.4.4 PLANTAR PLATE REPAIR 87
9.5 WOUND CARE 87
9.5.1 ANKLE ULCER TREATMENT 88
9.5.2 NEUROPATHIC FOOT ULCER TREATMENT 88
10 ASIA PACIFIC FOOT AND ANKLE ALLOGRAFTS MARKET, BY PROCEDURE 89
10.1 OVERVIEW 90
10.2 MIDFOOT PROCEDURES 93
10.2.1 CUBOID FRACTURE 94
10.2.2 FIRST TARSOMETATARSAL JOINT ARTHRODESIS 94
10.2.3 MEDIAL COLUMN ARTHRODESIS 94
10.2.4 LISFRANC 94
10.2.5 MEDIAL CUNEIFORM DORSAL OPENING WEDGE (COTTON) OSTEOTOMY 94
10.2.6 NAVICULAR CUNEIFORM ARTHRODESIS 94
10.2.7 NAVICULAR FRACTURE 94
10.2.8 OTHER MIDFOOT PROCEDURES 94
10.3 HIND-FOOT PROCEDURES 94
10.3.1 CALCANEAL FRACTURE 95
10.3.2 LATERAL COLUMN LENGTHENING 95
10.3.3 TALONAVICULAR JOINT ARTHRODESIS 96
10.3.4 TRIPLE ARTHRODESIS 96
10.3.5 OTHER HINDFOOT PROCEDURES 96
11 ASIA PACIFIC FOOT AND ANKLE ALLOGRAFTS MARKET, BY END USER 97
11.1 OVERVIEW 98
11.2 HOSPITALS 101
11.3 ORTHOPEDIC CLINICS 101
11.4 AMBULATORY SURGICAL CENTERS 102
11.5 ACADEMIC AND RESEARCH INSTITUTES 103
11.6 OTHER END USERS 104

12 ASIA PACIFIC FOOT AND ANKLE ALLOGRAFT MARKET, BY REGION 105
12.1 ASIA-PACIFIC 106
12.1.1 CHINA 114
12.1.2 INDIA 117
12.1.3 JAPAN 120
12.1.4 AUSTRALIA 123
12.1.5 SOUTH KOREA 126
12.1.6 SINGAPORE 129
12.1.7 INDONESIA 132
12.1.8 THAILAND 135
12.1.9 MALAYSIA 138
12.1.10 PHILIPPINES 141
12.1.11 REST OF ASIA-PACIFIC 144
13 ASIA PACIFIC FOOT AND ANKLE ALLOGRAFTS MARKET: COMPANY LANDSCAPE 145
13.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 145
14 SWOT ANALYSIS 146
15 COMPANY PROFILE 147
15.1 LIFENET HEALTH 147
15.1.1 COMPANY SNAPSHOT 147
15.1.2 COMPANY SHARE ANALYSIS 147
15.1.3 PRODUCT PORTFOLIO 148
15.1.4 RECENT DEVELOPMENTS 149
15.1.4.1 CONFERENCE 149
15.1.4.2 PRODUCT LAUNCH 150
15.2 ZIMMER BIOMET 151
15.2.1 COMPANY SNAPSHOT 151
15.2.2 REVENUE ANALYSIS 151
15.2.3 COMPANY SHARE ANALYSIS 152
15.2.4 PRODUCT PORTFOLIO 152
15.2.5 RECENT DEVELOPMENT 152
15.2.5.1 PARTNERSHIP 152
15.3 JOHNSON & JOHNSON SERVICES, INC. 153
15.3.1 COMPANY SNAPSHOT 153
15.3.2 REVENUE ANALYSIS 153
15.3.3 COMPANY SHARE ANALYSIS 154
15.3.4 PRODUCT PORTFOLIO 154
15.3.5 RECENT DEVELOPMENTS 154
15.3.5.1 EVENT 154
15.3.5.2 PRODUCT LAUNCH 154
15.4 INTEGRA LIFESCIENCES 155
15.4.1 COMPANY SNAPSHOT 155
15.4.2 REVENUE ANALYSIS 155
15.4.3 COMPANY SHARE ANALYSIS 156
15.4.4 PRODUCT PORTFOLIO 156
15.4.5 RECENT DEVELOPMENTS 156
15.4.5.1 POSITIVE CLINICAL OUTCOME 156
15.4.5.2 AGREEMENT 156
15.4.5.3 ACQUISITION 157
15.5 CONMED CORPORATION (2022) 158
15.5.1 COMPANY SNAPSHOT 158
15.5.2 REVENUE ANALYSIS 158
15.5.3 COMPANY SHARE ANALYSIS 159
15.5.4 PRODUCT PORTFOLIO 159
15.5.5 RECENT DEVELOPMENT 160
15.5.5.1 ACQUISITION 160
15.6 ALLOSOURCE 161
15.6.1 COMPANY SNAPSHOT 161
15.6.2 PRODUCT PORTFOLIO 161
15.6.3 RECENT DEVELOPMENT 162
15.6.3.1 PRODUCT LAUNCH 162
15.7 ALON SOURCE GROUP 163
15.7.1 COMPANY SNAPSHOT 163
15.7.2 PRODUCT PORTFOLIO 163
15.7.3 RECENT DEVELOPMENT 163
15.8 AMNIOX MEDICAL INC. 164
15.8.1 COMPANY SNAPSHOT 164
15.8.2 PRODUCT PORTFOLIO 164
15.8.3 RECENT DEVELOPMENT 164
15.8.3.1 PARTNERSHIP 164
15.9 ARTHREX 165
15.9.1 COMPANY SNAPSHOT 165
15.9.2 PRODUCT PORTFOLIO 165
15.9.3 RECENT DEVELOPMENT 165
15.9.3.1 PRODUCT LAUNCH 165
15.10 BIOVENTUS 166
15.10.1 COMPANY SNAPSHOT 166
15.10.2 REVENUE ANALYSIS 166
15.10.3 PRODUCT PORTFOLIO 167
15.10.4 RECENT DEVELOPMENT 167
15.10.4.1 CO-DEVELOPMENT 167
15.11 BONE BANK ALLOGRAFTS 168
15.11.1 COMPANY SNAPSHOT 168
15.11.2 PRODUCT PORTFOLIO 168
15.11.3 RECENT DEVELOPMENTS 168
15.11.3.1 PARTNERSHIP 168
15.12 GLOBUS MEDICAL 169
15.12.1 COMPANY SNAPSHOT 169
15.12.2 REVENUE ANALYSIS 169
15.12.3 PRODUCT PORTFOLIO 170
15.12.4 RECENT DEVELOPMENTS 170
15.12.4.1 M&A 170
15.13 INSTITUT STRAUMANN 171
15.13.1 COMPANY SNAPSHOT 171
15.13.2 REVENUE ANALYSIS 171
15.13.3 PRODUCT PORTFOLIO 172
15.13.4 RECENT DEVELOPMENT 172
15.14 JRF ORTHO 173
15.14.1 COMPANY SNAPSHOT 173
15.14.2 PRODUCT PORTFOLIO 173
15.14.3 RECENT DEVELOPMENT 174
15.14.3.1 PARTNERSHIP 174
15.15 NVISION BIOMEDICAL TECHNOLOGIES. 175
15.15.1 COMPANY SNAPSHOT 175
15.15.2 PRODUCT PORTFOLIO 175
15.15.3 RECENT DEVELOPMENT 175
15.15.3.1 ACQUISITION 175
15.16 PARAGON28, INC. 176
15.16.1 COMPANY SNAPSHOT 176
15.16.2 REVENUE ANALYSIS 176
15.16.3 PRODUCT PORTFOLIO 177
15.16.4 RECENT DEVELOPMENT 177
15.16.4.1 ACQUISITION 177
15.17 ORGANOGENESIS INC 178
15.17.1 COMPANY SNAPSHOT 178
15.17.2 REVENUE ANALYSIS 178
15.17.3 PRODUCT PORTFOLIO 179
15.17.4 RECENT DEVELOPMENTS 179
15.17.4.1 CONFERENCE 179
15.17.4.2 ACQUISITION 179
15.18 SMITH + NEPHEW 180
15.18.1 COMPANY SNAPSHOT 180
15.18.2 REVENUE ANALYSIS 180
15.18.3 PRODUCT PORTFOLIO 181
15.18.4 RECENT DEVELOPMENTS 181
15.18.4.1 EVENT 181
15.18.4.2 ACQUISITION 181
15.19 STRYKER 182
15.19.1 COMPANY SNAPSHOT 182
15.19.2 REVENUE ANALYSIS 182
15.19.3 PRODUCT PORTFOLIO 183
15.19.4 RECENT DEVELOPMENT 183
16 QUESTIONNAIRE 184
17 RELATED REPORTS 187

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.